Generalized Cost-Effectiveness Analysis to Assess Treatment Value in Hepatitis C
This article estimates the comprehensive value of direct-acting antivirals for the treatment of hepatitis C virus using a generalized cost-effectiveness analysis.
Understanding and Improving Value Frameworks With Real-World Patient Outcomes
New value frameworks should incorporate real-world evidence that reflects patient treatment behavior, adherence to medication, and equity concerns arising from disparities in care.
Value of Improved Lipid Control in Patients at High Risk for Adverse Cardiac Events
Reducing lipid levels in high-risk patients can significantly reduce disease burden and, depending on final negotiated prices, PCSK9 inhibitors can make an economic contribution to this goal.
